In the era of the rapid development of cancer immunotherapy, there is a high level of interest
in the application of cell-released small vesicles that stimulate the immune system. As cell …

Immune cell–derived exosomes can increase immunity against tumors. In contrast, tumor-
derived exosomes can reduce the immunity and can change the tumor microenvironment to …

Neoantigen-based cancer vaccines are emerging as promising tumor therapies, but
enhancement of immunogenicity can further improve therapeutic outcomes. Here, we …

Dendritic cell (DC) vaccine–based immunotherapy for glioblastoma multiforme (GBM) has
shown apparent benefit in animal experiments and early-phase clinical trials, but the …

Extracellular vesicles, especially exosomes, have been explored for cancer immunotherapy.
The initial studies made use of autologous B‐cell or dendritic cell‐derived exosomes, with …

Cancer immunotherapy has revolutionized the approach to cancer treatment of malignant
tumors by harnessing the body's immune system to selectively target cancer cells. Despite …

Cancer stands as a prominent contributor to global mortality rates, necessitating immediate
attention toward the exploration of its treatment options. Extracellular vesicles have been …

Identification of immunogenic tumor antigens that are efficiently processed and delivered by
dendritic cells to prime the immune system and to induce an appropriate immune response …

Tumor-derived exosomes (TDEs) play pivotal roles in several aspects of cancer biology. It is
now evident that TDEs also favor tumor growth by negatively affecting anti-tumor immunity …

Tumor-derived exosomes (TEX) can induce a specific antitumor immune response and have
been developed as a promising tumor vaccine. Despite promising preclinical data, TEX …